Insmed discontinues development of skin condition drug after mid-stage study miss [Yahoo! Finance]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
The drug, brensocatib, did not meet the main goal of reducing painful lumps in patients with hidradenitis ?suppurativa, the company ?said. "While we are disappointed in the results, we hope that ?insights gained from this study will contribute to the broader scientific understanding of ?HS," said ?Insmed's Chief ?Medical Officer, Martina Flammer. The ?drug was generally safe, with no new safety signals, the company said. It plans to present the data at a future meeting. Insmed said in December ?it discontinued the development ?of brensocatib as a ?treatment for ?a chronic sinus condition after ?a trial failure. Brensocatib, branded ?as Brinsupri, ?is approved in the U.S. to treat non-cystic fibrosis bronchiectasis, a chronic ?lung ?condition characterized by permanently damaged airways. (Reporting ?by Christy Santhosh in Bengaluru; Editing ?by Shreya Biswas)
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed (INSM) was upgraded by Raymond James Financial, Inc. to "moderate buy".MarketBeat
- Insmed (INSM) is now covered by Raymond James Financial, Inc.. They set an "outperform" rating and a $200.00 price target on the stock.MarketBeat
- Insmed freezes Brinsupri's HS programme on Phase II failure [Yahoo! Finance]Yahoo! Finance
- Insmed Provides Clinical Update on Phase 2b CEDAR StudyPR Newswire
- Insmed (INSM) Is Up 10.0% After Positive ENCORE Data Position ARIKAYCE For Earlier MAC Use [Yahoo! Finance]Yahoo! Finance
INSM
Earnings
- 2/19/26 - Miss
INSM
Sec Filings
- 4/8/26 - Form 4
- 4/7/26 - Form 8-K
- 4/6/26 - Form 144
- INSM's page on the SEC website